PHOENIX, Ariz., Nov. 06, 2018 (GLOBE NEWSWIRE) — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) (the “Company”) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. CEO Co-Founder, Eyal Barad, talked with Stock Day’s Everett Jolly.
“Cannabics Pharmaceuticals started about 5 years ago and today is mostly focused on the palliative and anti-tumor effects cannabinoids with cancer,” explained Barad. “We are truly focused on cancer, both the side effects and anti-tumor effects
...read more at https://globenewswire.com/news-release/2018/11/06/1646038/0/en/Cannabics-Pharmaceuticals-Inc-CEO-talks-with-Uptick-Newswire-s-Stock-Day-Podcast-About-Cancer-Research-in-the-Cannabinoid-Sector.html